Stockreport

Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]

Dianthus Therapeutics, Inc.  (DNTH) 
PDF goal (20 confirmed NCAT responders) and raised the Part A responder assumption to 50%, leading it to drop the 600 mg arm and make Part B a two-arm randomized withdrawal [Read more]